People of Packaging · 7 May 2026 · 28m
Lauren Rockteacher, founder of Proof and Panel, explains the critical importance of regulatory compliance in food and dietary supplement labeling, distinguishing between the two categories based on structure-function claims. She warns against relying on AI for regulatory advice, noting that while it can be a starting point, it often hallucinates specific code sections, leading to non-compliant labels. Rockteacher emphasizes that her 200+ checkpoint review process prevents costly recalls and waste by ensuring conditional labeling elements are handled correctly before printing.
Where this conversation describes AI being used to build or deliver a product. Part of the AI in practice tracker.
DesignChatGPT
Lauren Rockteacher uses AI to generate potential regulatory answers and citations for label compliance questions, which she then manually verifies against official sources to correct inaccuracies.
“I I like to, in my spare time, go to AI and throw in a couple questions that I may have had to go back and look into the regulations for. And a lot of times it'll give me an answer that sounds great.”
Speaker 2 · Hear it at 19:21
early-stage companies
Other shows on the same ground, closest first.
Lauren Handel, founder of Handel Food Law, explains the regulatory framework and litigation risks for CPG brands, distinguishing between FDA-regulated foods and USDA-regulated products. She details specific claim categories including nutrient content, 'natural,' 'organic,' and health benefits, emphasizing that consistency across packaging, websites, and advertising is essential to avoid costly class-action lawsuits. Handel advises founders to understand the difference between regulatory consultants and attorneys, noting that legal advice offers privilege and risk assessment that consultants cannot provide, while recommending third-party certifications to mitigate exposure to litigation.
Mike Drues, an industry veteran with over 30 years of experience, joins host Etienne Nichols to discuss the dangers of 'boneheaded' regulatory mistakes in MedTech, specifically focusing on the non-delegable responsibility of manufacturers. They analyze the first FDA warning letter issued for GMP violations related to AI, where a company used AI to generate specifications without process validation, arguing that AI cannot replace human judgment or the Quality Unit. The conversation extends to the debate on individual accountability in warning letters, the distinction between wellness and regulated devices, and new FDA programs like the TEMPO pilot and Breakthrough Device Designation (BDD).
Chris Szigeti, a tech consultant and founder of the pre-launch honey brand Froth and Honey, explains how early-stage CPG founders can leverage AI to reduce overhead and accelerate development. He demystifies foundational models like ChatGPT, Claude, and Gemini, distinguishing between general and reasoning models, and advocates for using 'Deep Research' for market analysis. Szigeti shares practical strategies for CPG brands, including using AI as a virtual advisory board, generating conceptual packaging designs, and building websites with tools like v0, while warning against losing brand authenticity.
Host Etienne Nichols analyzes the FDA's warning letter to Purolea Cosmetics Lab, arguing that the citation was not a crackdown on AI but a failure of quality system oversight and process validation. He explains that while Purolea used AI agents to draft specifications, the core violation was the lack of human review and accountability under 21 CFR 211.22. Nichols outlines a three-part validation framework for AI/ML-based Software as a Medical Device (SaMD), emphasizing the separation of training, validation, and holdout test data. He concludes by listing essential regulatory standards and five concrete questions to assess if a quality system is ready for FDA AI inspections.
Darshan Kulkarni, an FDA regulatory attorney and Adjunct Law Professor at Drexel University, explains the distinction between regulatory and legal compliance in the life sciences industry. He details how the First Amendment influences US promotional compliance, particularly regarding off-label speech and the 'truthful not misleading' standard established by recent court cases. Kulkarni also discusses the operational differences between FDA divisions for drugs (OPDP) and devices (CDRH), noting the latter's limited enforcement resources, and highlights the implications of the Sunshine Act on physician interactions.
The summary, chapters and topics are generated from the episode’s audio by this directory, not written by People of Packaging. The episode itself belongs to its publisher.